Neogen Corp. (NASDAQ:NEOG) CEO James L. Herbert sold 36,000 shares of the company’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $61.00, for a total transaction of $2,196,000.00. Following the completion of the sale, the chief executive officer now directly owns 904,212 shares of the company’s stock, valued at approximately $55,156,932. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Shares of Neogen Corp. (NASDAQ:NEOG) traded up 1.39% on Thursday, hitting $61.26. 55,246 shares of the company traded hands. The firm has a market capitalization of $2310.05 billion, a P/E ratio of 61.88 and a beta of 1.50. Neogen Corp. has a 1-year low of $43.79 and a 1-year high of $62.55. The firm’s 50-day moving average is $54.65 and its 200 day moving average is $54.50.

Neogen Corp. (NASDAQ:NEOG) last posted its quarterly earnings data on Tuesday, September 27th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. The company earned $83.65 million during the quarter. Neogen Corp. had a net margin of 11.25% and a return on equity of 9.36%. The firm’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.25 earnings per share. On average, analysts anticipate that Neogen Corp. will post $1.12 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Neogen Corp. (NASDAQ:NEOG)

Several equities research analysts have weighed in on NEOG shares. Craig Hallum raised shares of Neogen Corp. from a “hold” rating to a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research cut shares of Neogen Corp. from a “buy” rating to a “hold” rating in a research report on Friday, September 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $58.25.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Neogen Corp. by 126.9% in the first quarter. BlackRock Inc. now owns 2,512 shares of the company’s stock worth $126,000 after buying an additional 1,405 shares in the last quarter. State Street Corp raised its stake in shares of Neogen Corp. by 3.2% in the first quarter. State Street Corp now owns 759,676 shares of the company’s stock worth $38,252,000 after buying an additional 23,679 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Neogen Corp. by 5.6% in the first quarter. Geode Capital Management LLC now owns 257,398 shares of the company’s stock worth $12,959,000 after buying an additional 13,715 shares in the last quarter. Kennedy Capital Management Inc. raised its stake in shares of Neogen Corp. by 2.6% in the first quarter. Kennedy Capital Management Inc. now owns 31,621 shares of the company’s stock worth $1,592,000 after buying an additional 790 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Neogen Corp. by 107.1% in the second quarter. BNP Paribas Arbitrage SA now owns 11,714 shares of the company’s stock worth $659,000 after buying an additional 6,058 shares in the last quarter. 86.99% of the stock is owned by institutional investors.

Neogen Corp. Company Profile

Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation.

5 Day Chart for NASDAQ:NEOG

Receive News & Stock Ratings for Neogen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen Corp. and related stocks with our FREE daily email newsletter.